* To study HIV-1 sequence dynamics and HIV-1 evolution in donor-recipient pairs in relation to host and viral factors.* To detect and characterize the differences in transmitted virus in donor-recipient pairs as soon as possible after transmission.
ID
Source
Brief title
Condition
- Viral infectious disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
* Sequence of the viral genome that is present in the HIV-1 donor as close as
possible to the time of HIV-1 transmission.
* Virus diversity (quasispecies) in the donor-recipient pairs half a year after
HIV-1 transmission.
* HLA type of donor-recipient pairs, availability of replication competent
(pseudo)viruses from donor and recipient.
Secondary outcome
The relation between viral sequence dynamics and:
* The HLA type of donor and recipient
* The autologous neutralization profile
* Host CTL responses
* Viral fitness
Background summary
It is known that HIV-1 variants escape cellular and humoral immunity in the
host. This may however have an impact on viral fitness and as a consequence,
escape mutations will revert in the face of declining immunity or upon
transmission to a new host. The aim of this study is to examine the dynamics of
escape mutations and reversions in relation to the HLA type of the HIV-1 donor
and the HLA type of the HIV-1 recipient. In addition, the same HIV-1 sequence
dynamics in relation to the specificity of the humoral immune response in HIV-1
donor-recipient pairs will be studied.
Study objective
* To study HIV-1 sequence dynamics and HIV-1 evolution in donor-recipient pairs
in relation to host and viral factors.
* To detect and characterize the differences in transmitted virus in
donor-recipient pairs as soon as possible after transmission.
Study design
Cohort study
Study burden and risks
Patients will have to come to the outpatient clinic in the AMC at least two
times, maximum three. Each visit will take approximately thirty minutes.
Sixteen blood samples will be drawn at baseline and 24 wks thereafter with a
maximum volume of 128 ml. This may cause some discomfort like a bruise.
There is no individual benefit for the patient to participate in this study,
but in general participation will benefit the understanding of the evolution of
recently transmitted HIV-1 which is of importance for HIV-1 vaccine
development.
Meibergdreef 9
1105 AZ Amsterdam
NL
Meibergdreef 9
1105 AZ Amsterdam
NL
Listed location countries
Age
Inclusion criteria
* HIV-1 infected partner(s) who are assumed to be the source of HIV-1 transmission (donor) of patients who present with primary HIV-1 infection at the *Primo-SHM* study (recipient) in the AMC (MEC 03/059).
* At least 18 years of age
Exclusion criteria
None
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL26574.018.09 |